All In Biotech

Free tool

FAERS Monitor: Zaltrap

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125418 or its brand name (Zaltrap, Ziv-Aflibercept). Reports on generic versions are filed under their own applications.

Reports

1,304

Serious

1,220

94% of reports

Hospitalization

592

Death reported

207

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea178
  • hypertension137
  • neutropenia105
  • asthenia73
  • vomiting68
  • proteinuria64
  • death61
  • nausea59
  • disease progression49
  • fatigue48
  • stomatitis43
  • abdominal pain42
  • pyrexia42
  • febrile neutropenia40
  • decreased appetite39

Reports by year received

View as table
YearReports
201220
2013120
2014114
2015105
2016109
2017115
2018258
2019184
202092
202128
202221
202341
202464
202519
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,855 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
proteinuriaSignal6454.542.93,298
neutropeniaSignal10512.510.41,102
stomatitisSignal4311.48.5400
hypertensionSignal13710.48.91,171
febrile neutropeniaSignal409.77.2305
disease progressionSignal496.75.1232
diarrhoeaSignal1784.43.9487
astheniaSignal733.12.5106
abdominal painSignal422.92.251
decreased appetiteSignal392.72.041
vomitingSignal682.31.952
pyrexia422.01.519
nausea591.20.92
death611.10.91
fatigue481.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.